Your event should be here ! To publish, manage, promote... To learn or to be formed ... Online registrations

Site language : English - Français
Ref : 31614
Event :5th Microbiome Movement Drug Development Summit 2020 - Digital Event

Dates :Monday October 19th, 2020 - Wednesday October 21st, 2020

Location :Online (Internet, Videoconferencing, ...)

Type :Conference & Seminar - International audience

Accreditation :--


 

Further information

The Microbiome Movement - Drug Development Summit continues to be the industry-leading forum to help forward thinking researchers from the pharmaceutical, biotech and academic community pursue the causal role of the human microbiome in disease, to create a new generation of targeted treatments that demonstrate consistent clinical outcomes and predictable MoAs.

If you are, or would like to be, a player in the microbiome arena, this is the conference you should attend to not only hear the latest pre-clinical and clinical development from organizations developing microbiome-based therapeutics, biomarkers and diagnostics, but also to make long-lasting connections that will accelerate your microbiome developments forward, and help translate this promising science into a reality for patients.

- Pre-Clinical Development and Mechanisms of Microbiome-based Therapeutics
Learn how industry and academic pioneers are developing novel microbiome platforms to identify new targets and therapeutics across a range of microbiome-targeting modalities and disease phenotypes
- Clinical Development, Manufacturing and Commercialization of Live Biotherapeutics
As the industry prepares for pivotal clinical readouts this summer, this year's discussion will give you the knowledge and insight required to navigate through the specific translational, clinical and manufacturing challenges for live biotherapeutics
- Microbiome-based Biomarkers, Diagnostics and Patient Stratification
Mine the human microbiome to discover new biomarkers of disease and help predict response, understand drug metabolism and develop non-invasive diagnostic tools
- Applications in Oncology
Gain a comprehensive insight into the most exciting disease target in microbiome research today with case-studies and discussion from leading cancer researchers, oncology-specific clinicians and the pharmaceutical industry

URLs:
Website: https://go.evvnt.com/613499-0?pid=4319
Tickets: https://go.evvnt.com/613499-2?pid=4319
Brochure: https://go.evvnt.com/613499-3?pid=4319

Time: 09:00 to 17:00

Prices:
Full Access: Main Conference + 3 Workshops - Drug Developers: Pharma and Biotech Rate: USD 2896.00,
Conference + 2 Workshops - Drug Developers: Pharma and Biotech Rate: USD 2597.00,
Conference + 1 Workshop - Drug Developers: Pharma and Biotech Rate: USD 2298.00,
Conference Only - Drug Developers: Pharma and Biotech Rate: USD 1999.00,
Full Access: Main Conference + 3 Workshops - Start-Up, Academic and Not-For-Profit Rate: USD 1796.00,
Conference + 2 Workshops - Start-Up, Academic and Not-For-Profit Rate: USD 1597.00,
Conference + 1 Workshop - Start-Up, Academic and Not-For-Profit Rate: USD 1398.00,
Conference Only - Start-Up, Academic and Not-For-Profit Rate: USD 1199.00

Speakers: Libusha Kelly, Associate Professor Albert Einstein College of Medicine, Jackie Papkoff, Chief Scientific Officer Assembly Biosciences, Sara Ferrando, Martinez Research Scientist AstraZeneca, David Donabedian, CEO Axial Therapeutics, Stacy Kahn, MD, Attending Physician Boston Children’s Hospital, Jessica Allegretti, MD, Director Clinical Trials Brigham and Women's Hospital, Gerard Honig, Associate Director, Research Innovation Crohn's and Colitis Foundation, Aaron Del Duca, VP Microbiome Platform DayTwo, Sonia Timberlake, VP Research Finch Therapeutics, Cynthia Sears, MD, Professor of Medicine John Hopkins Medicine, Alison Lawton, CEO Kaleido Biosciences, Sahil Khanna, MD, Associate Professor of Medicine and Consultant Mayo Clinic, Geoffrey Hannigan, Associate Principal Scientist Merck Exploratory Science Center, Nathan Crook, Assistant Professor - Chemical and Biomolecular Engineering NC State, Wes Whitaker, Chief Scientific Officer Novome Biotechnologies, Majdi Osman, MD, Clinical Program Director OpenBiome, Theresa LaVallee, VP Translational Medicine and Regulatory Affairs Parker Institute for Cancer Immunotherapy, Colleen Cutcliffe, Co-founder and CEO Pendulum Therapeutics, Barbara McGovern, MD, VP Medical Affairs Seres Therapeutics, Matthew Henn, CSO Seres Therapeutics, Bruce Roberts, Chief Scientific Officer Vedanta Biosciences, Marcus Rauch, Chief Scientific Officer AlphaBiomics, Mark Bamforth, President and CEO Arranta Bio, Jackie Papkoff, Chief Scientific Officer Assembly Biosciences, Assaf Oron, Chief Business Officer BiomX, Adrien Nivoliez, CEO Biose Industrie, Chris Reyes, Co-Founder and CEO Bloom Science, Jeffrey Heiser, Director Microbiology Boston Analytical, Luc Sterkman, CEO Caelus Health, Stephen Conafay, Principal and Founder Conafay Group, Dan Knights, CEO Corebiome, Arne Materna, Vice President Product CosmosID, Christophe Bonny, CSO Enterome, Daniel van der Lelie, Chief Scientific Officer Gusto Global, Dirk Gevers, Global Head Janssen Human Microbiome Institute, Johan van Hylckama Vlieg, Chief Scientific Officer Kaleido Biosciences, Paul Peter Tak, President and CEO Kintai Therapeutics, Stacy Burns-Guydish, VP Biotherapeutics Development and Manufacturing List Laboratories, Tuval Ben-Yehezkel, CEO Loop Genomics, Jason Ryan, Head of Upstream Luina Bio, Gunjan Singh Thakur, Senior Scientist Computational Biology Merck Exploratory Science Center, Xue Liang, Microbiome Scientist Merck Exploratory Science Center, Will DeLoache, Co-Founder and CSO Novome Biotechnologies, Mohan Iyer, Chief Operating Officer Pendulum Therapeutics, Tomas de Wouters, Co-Founder and CEO PharmaBiome, Keri Donaldson, CEO Prescient Metabiomics, Massimo Marzorati, CEO ProDigest, Ryan Wilson, Head of Live-Bioprogrammes Quay Pharma, Julius Goepp, Founder and CEO Scaled Microbiomics, Stacy Townsend, Director of Pre-Clinical Development SciBac, Ken Blount, CSO Rebiotix, Barbara McGovern, MD, VP Medical Affairs Seres Therapeutics, Matthew Henn, CSO Seres Therapeutics, Eric Shaff, CEO Seres Therapeutics, John Aunins, Chief Technology Officer Seres Therapeutics, Nikole Kimes, Co-founder and CSO Siolta Therapeutics, Ricardo Valladares, VP Research and Development Siolta Therapeutics, Eric Van der Helm, Head of Synthetic Biology and Bioinformatics SNIPR Biome, Gerardo Toledo, Co-Founder and CEO Solarea Bio, Jeffrey Hymes, Scientist Symberix, Yogesh Mudaliar, Research Investigator Drug Product Development Takeda Pharmaceuticals, Gregory Lambert, CEO and VP R and D TargEDys, Benjamin Lelouvier, Chief Scientific Officer Vaiomer, Bernat Olle, CEO Vedanta Biosciences, Ryan Toma, Research Scientist Viome, Matthew Meyerson, Professor and Principal Investigator Dana-Farber Cancer Institute, Alexander Kostic, Assistant Professor Harvard Medical School, Yang-Yu Liu, Assistant Professor of Medicine Harvard Medical School, Yangcong Zhang, Postodoctoral Fellow Huttenhower Lab Harvard T.H. Chan School of Public Health, Cynthia Sears, MD, Professor of Medicine John Hopkins Medicine, Christine Pierce, Assistant Member - Department of Cancer Epidemiology Moffit Cancer Center and Research Institute, Jonathan Peled, MD, Medical Oncologist Memorial Sloan Kettering Cancer Center, Aida Habtezion, MD, Principal Investigator Stanford University, Betty Theriault, DVM, Assistant Professor University of Chicago, Nikki Klatt, Associate Professor Pediatrics University of Miami, Stephan Patrick, Rosshart, Principal Investigator and Group Leader Translational Microbiome Research University Medical Center Freiburg, Hariom Yadav, Assistant Professor, Molecular Medicine Wake Forest School of Medicine, Speaker TBC, CBER FDA

Further information

To access the information you need to be connected. Creating an account is easy and free!

Log to your account
Register on Doctorama

Details

5th Microbiome Movement Drug Development Summit 2020 - Digital Event Pharmacy
--
Everyone
1000 -- --
English

Recommend this event